Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., Van Kerrebroeck, P., Victor, A., & Wein, A. (2003) · Urology · doi:10.1016/s0090-4295(02)02243-4 · Cited by 3,220 · cited 1×
“Overactive bladder (OAB), defined as lower urinary tract symptoms of urgency with or without urge urinary incontinence (UUI), usually with frequency and nocturia [1], affects approximately 17% of adults in European countries [2] and has a substantial impact on different parameters, including quality of life (QoL) [3].”
Milsom, I., Abrams, P., Cardozo, L., Roberts, R. G., Thüroff, J., & Wein, A. J. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02228.x · Cited by 1,752 · cited 1×
“Overactive bladder (OAB), defined as lower urinary tract symptoms of urgency with or without urge urinary incontinence (UUI), usually with frequency and nocturia [1], affects approximately 17% of adults in European countries [2] and has a substantial impact on different parameters, including quality of life (QoL) [3].”
Coyne, K. S., Sexton, C. C., Irwin, D. E., Kopp, Z. S., Kelleher, C. J., & Milsom, I. (2008) · BJU International · doi:10.1111/j.1464-410x.2008.07601.x · Cited by 837 · cited 1×
“Overactive bladder (OAB), defined as lower urinary tract symptoms of urgency with or without urge urinary incontinence (UUI), usually with frequency and nocturia [1], affects approximately 17% of adults in European countries [2] and has a substantial impact on different parameters, including quality of life (QoL) [3].”
Chapple, C. R., Khullar, V., Gabriel, Z., Muston, D., Bitoun, C. E., & Weinstein, D. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.047 · Cited by 769 · cited 1×
“Conservative treatments (ie, lifestyle modifications, pelvic floor exercises, bladder training, and anticholinergic regimens) may result in insufficient improvements and in low compliance because of bothersome adverse events [4,5].”
Quality of life of persons with urinary incontinence: Development of a new measure
Wagner, T. H., Patrick, D. L., Bavendam, T. G., Martin, M. L., & Buesching, D. E. (1996) · Urology · doi:10.1016/s0090-4295(99)80384-7 · Cited by 513 · cited 1×
“QoL was assessed using the Incontinence Quality of Life (I-QoL) questionnaire, a validated disease-specific 22-item score [14,15] evaluating both the distress and impact of urinary incontinence, and the EQ-5D visual analogue scale”
Patrick, D. L., Martin, M. L., Bushnell, D. M., Yalcin, I., Wagner, T. H., & Buesching, D. P. (1999) · Urology · doi:10.1016/s0090-4295(98)00454-3 · Cited by 509 · cited 1×
“QoL was assessed using the Incontinence Quality of Life (I-QoL) questionnaire, a validated disease-specific 22-item score [14,15] evaluating both the distress and impact of urinary incontinence, and the EQ-5D visual analogue scale”
Dmochowski, R., Chapple, C., Nitti, V. W., Chancellor, M., Everaert, K., Thompson, C., Daniell, G., Zhou, J., & Haag-Molkenteller, C. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.08.021 · Cited by 406 · cited 3×
“[10] observed an improved QoL with 100 U and 150 U BoNTA injections at month 6, whereas no improvement could be observed with a 50 U dose.”
InfluentialKarsenty, G., Denys, P., Amarenco, G., De Seze, M., Gamé, X., Haab, F., Kerdraon, J., Perrouin-Verbe, B., Ruffion, A., Saussine, C., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.10.013 · Cited by 347 · cited 1×
“BoNTA injections have largely been studied in patients with neurogenic OAB [6].”
Self-citationRefractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection
Brubaker, L., Richter, H. E., Visco, A., Mahajan, S., Nygaard, I., Braun, T. M., Barber, M. D., Menefee, S., Schaffer, J., Weber, A. M., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.03.028 · Cited by 328 · cited 2×
“[8]; they observed a significant 60% response rate in Patient Global Impression of Improvement (PGI-I) score 4 compared to placebo at least 2 mo after the initial 200 U BoNTA injection.”
Apostolidis, A., Prokar Dasgupta, A., Denys, P., Elneil, S., Fowler, C. J., Giannantoni, A., Karsenty, G., Schulte‐Baukloh, H., Schurch, B., & Wyndaele, J. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.009 · Cited by 315 · cited 1×
“The optimal dosing of BoNTA still remains to be defined [13].”
Self-citationSahai, A., Khan, M. S., Dasgupta, P., & GKT Botulinum Study Group (2007) · Journal of Urology · doi:10.1016/j.juro.2007.01.130 · Cited by 312
Flynn, M. K., Amundsen, C. L., Perevich, M., Liu, F., & Webster, G. D. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.117 · Cited by 198 · cited 2×
“However, only a few articles described the effect of onabotulinumtoxinA in patients with iOAB [7], and only four randomised, placebo-controlled studies reported either the effect of 200 U BoNTA injections [8,9] or compared the efficacy of different BoNTA doses (50, 100, 150, 200, and 300 U) [10–12].”
Zuber, M., Sebald, M., Bathien, N., de Recondo, J., & Rondot, P. (1993) · Neurology · doi:10.1212/wnl.43.9.1715 · Cited by 195 · cited 1×
“BoNTA antibodies were measured at day – 15 and at month 6 as previously described [17].”
MethodAnger, J. T., Weinberg, A. E., Suttorp, M. J., Litwin, M. S., & Shekelle, P. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.02.009 · Cited by 134 · cited 1×
“However, only a few articles described the effect of onabotulinumtoxinA in patients with iOAB [7], and only four randomised, placebo-controlled studies reported either the effect of 200 U BoNTA injections [8,9] or compared the efficacy of different BoNTA doses (50, 100, 150, 200, and 300 U) [10–12].”
The Placebo Effect in the Pharmacologic Treatment of Patients with Lower Urinary Tract Symptoms
van Leeuwen, J. H. S., Castro, R. S., Busse, M., & Bemelmans, B. L. H. (2006) · European Urology · doi:10.1016/j.eururo.2006.05.014 · Cited by 131 · cited 1×
“In addition, we observed a high placebo effect, a phenomenon that is often observed in OAB studies, using patient-reported data [20,21].”
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
Lee, S., Malhotra, B. K., Creanga, D. L., Carlsson, M. O., & Glue, P. (2009) · BMC Medical Research Methodology · doi:10.1186/1471-2288-9-55 · Cited by 58
Campbell, J. D., Gries, K. S., Watanabe, J. H., Ravelo, A., Dmochowski, R. R., & Sullivan, S. D. (2009) · BMC Urology · doi:10.1186/1471-2490-9-18 · Cited by 30
Cited by
Gormley, E. A., Lightner, D. J., Faraday, M., & Vasavada, S. P. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.01.087 · Cited by 789
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.09.079 · Cited by 710
Metadata
- Authors
- Denys, P., Le Normand, L., Ghout, I., Costa, P., Chartier-Kastler, E., Grise, P., Hermieu, J.-F., Amarenco, G., Karsenty, G., Saussine, C., & Barbot, F.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 61
- Issue
- 3
- Pages
- 520-529
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2021257414
- Cited by
- 164
- References
- 18
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.